Iperia/Sentus QP Study

NCT ID: NCT02181686

Last Updated: 2015-07-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

152 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to confirm the safety and efficacy of the new Sentus OTW QP LV lead and Iperia ICD family. The study focuses on the safety and efficacy of the QP device system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Tachyarrhythmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sentus QP group

Patients with standard indication for CRT-D therapy who will be implanted with Sentus QP LV lead and the BIOTRONIK HF-T QP device.

No interventions assigned to this group

VR-T/DR-T group

Patients with standard indication for ICD therapy who will be implanted with either single chamber ICD or dual chamber ICD of the Iperia ICD family

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is able to understand the nature of the study and provides written informed consent.
* Patient meets a standard indication for CRT-D (Sentus QP group) or ICD therapy.
* Patient is able and willing to complete the planned follow-up visits at the investigational site.
* Patient accepts the Home Monitoring® concept.
* Age is ≥ 18 years.
* Sentus QP group only: Patient is a candidate for a new (de novo) implant or an upgrade from an existing ICD or pacemaker utilizing a BIOTRONIK Sentus QP lead

Exclusion Criteria

* Patient has a standard contraindication for CRT-D (Sentus QP group) or ICD therapy.
* Sentus QP group only: Currently implanted with an endocardial or epicardial LV lead or had prior attempt to place a LV lead.
* Sentus QP group only: Cardiac surgery procedure (coronary bypass graft, valve surgery, or ablation) that is planned to occur within 3 months after implantation.
* Patient is expected to receive ventricular assist device or heart transplantation within the next 3 months.
* Patient is pregnant or breastfeeding.
* Life expectancy of less than 3 months
* Participating in another cardiac clinical investigation with active treatment arm.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotronik SE & Co. KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Werner Jung, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Schwarzwald-Baar Klinikum Villingen-Schwenningen, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Landesklinikum

Sankt Pölten, , Austria

Site Status

Aalborg University Hospital

Aalborg, , Denmark

Site Status

Odense University Hospital

Odense, , Denmark

Site Status

Aarhus University Hospital

Skejby, , Denmark

Site Status

Jyväskylä Central Hospital

Jyväskylä, , Finland

Site Status

Herz- und Diabetes Zentrum

Bad Oeynhausen, , Germany

Site Status

SRH Wald-Klinikum

Gera, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

UKSH Campus Lübeck

Lübeck, , Germany

Site Status

Märkische Kliniken Lüdenscheid

Lüdenscheid, , Germany

Site Status

Kliniken Maria Hilf GmbH

Mönchengladbach, , Germany

Site Status

Klinikum München-Bogenhausen

Munich, , Germany

Site Status

Johanniter Krankenhaus

Stendal, , Germany

Site Status

Schwarzwald-Baar Klinikum

Villingen-Schwenningen, , Germany

Site Status

Ospedale Pugliese Ciaccio

Catanzaro, , Italy

Site Status

Paul Stradins Clinical University Hospital

Riga, , Latvia

Site Status

University Medical Center Groningen

Groningen, , Netherlands

Site Status

Isala Klinieken

Zwolle, , Netherlands

Site Status

National Heart Centre

Singapore, , Singapore

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Kantonsspital Lucerne

Lucerne, , Switzerland

Site Status

Cardiocentro Ticino

Lugano, , Switzerland

Site Status

Triemlispital Zurich

Zurich, , Switzerland

Site Status

Russels Hall Hospital

Brighton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Denmark Finland Germany Italy Latvia Netherlands Singapore Spain Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BIO|CONCEPT.BIOMONITOR III
NCT03850327 COMPLETED NA
MODULA Modul 5 BEAT-HF
NCT00273091 COMPLETED
Mid-Q Response Study
NCT04180696 COMPLETED NA
ProMRI 3T ENHANCED Master Study
NCT02506569 COMPLETED
MultiPoint Pacing IDE Study
NCT01786993 COMPLETED PHASE3
S-ICD® System IDE Clinical Study
NCT01064076 COMPLETED NA